Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Alvotech announced it will release its financial results for the nine months and third quarter ended September 30, 2026, on November 11, 2026.
Stocks · News reference
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Alvotech birtir uppgjör fyrstu níu mánaða ársins 2026 þann 11. nóvember nk.
Alvotech announced it will release its nine-month financial results for 2026 on November 11, with a live webcast presentation scheduled for November 12. The company also received FDA approval for an enhanced SIMLANDI® manufacturing process that more than doubles output per batch, increasing manufacturing productivity and freeing capacity to support growing demand across its biosimilars portfolio.
Alvotech shares are trading higher after the company announced FDA approval for a new manufacturing process for SIMLANDI.
FDA Approves Alvotech’s Process 2.0 For SIMLANDI Drug Substance, More Than Doubling Output Per Batch Without Changing Upstream Manufacturing Scale
Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.
AstraZeneca Launches 'Meet Your Mark' Campaign to Promote Cancer Biomarker Testing
AstraZeneca has introduced a new public health campaign featuring actor Mark-Paul Gosselaar to encourage patients to discuss biomarker testing as a standard part of cancer care.